# A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

> **NCT03742973** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 2 (actual)

## Conditions studied

- Primary Biliary Cholangitis

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03742973
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-28
- **Primary completion:** 2019-09-26
- **Final completion:** 2019-09-26
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study was terminated due to enrollment futility.
- **Last updated:** 2020-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03742973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03742973, "A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03742973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*